A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients. (11th November 2019)

• Record Type: Journal Article
• Authors: Hung, Stanley Hughwa; Mutti Jaswal, Sumeet; Neil-Sztramko, Sarah Elizabeth; Kam, Julia W Y; Niksirat, Negin; C Handy, Todd; Liu-Ambrose, Teresa; Lim, Howard J; Hayden, Sherri; Gill, Sharlene; Campbell, Kristin L
• Is Part Of: Archives of clinical neuropsychology. Volume 35:Number 2(2020)
• Page Start: 226
• Page End: 232
• Publication Date: 2019-11-11
• Subjects: Electrophysiological studies -- Neurotoxicity -- Attention -- Colon cancer -- Cognition -- Chemotherapy -- Mind wandering -- Sustained attention; Clinical neuropsychology -- Periodicals; 616.805
• DOI: 10.1093/arclin/acz051
• Languages: English
• ISSNs: 0887-6177

Abstract

Abstract: Introduction: The purpose of this study was to describe the trajectory of cognitive function using neuropsychological tests and electrophysiological measures in individuals receiving 5FU/oxaliplatin chemotherapy for colon cancer. Methods: A total of 10 participants were tested at baseline (within 3 weeks of starting chemotherapy), 6 months (coinciding with the end of chemotherapy treatment), and 12 months (approximately 6 months post-chemotherapy). Participants completed neuropsychological tests and electrophysiology recordings of P300 event-related potential (ERP) elicited by a sustained attention to response task paired with experience sampling of attentional states (subjective reports of on-task or mind wandering). Results: No change in mean neuropsychological test performance was observed. Comparison of mean P300 ERP amplitudes as a function of attentional states (on-task vs. mind wandering) revealed no main effect of attentional state observed at baseline or 6 months, but a significant effect of attention was observed at 12 months, consistent with effects observed in healthy individuals. Conclusions: Future studies can consider sustained attention constructs when studying cognitive function in colon cancer patients.